Mochida Pharmaceutical Co (FRA:MFY) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:MFY Mochida Pharmaceutical Co Ltd FRA:MFY
70 GF Score
Price €16.70
GF Value €19.65
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Mochida Pharmaceutical Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:MFY vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mochida Pharmaceutical Co Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's Margin of Safety % (DCF Earnings Based) falls into.


FRA:MFY
70GF Score
Mochida Pharmaceutical Co Ltd FRA:MFY
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mochida Pharmaceutical Co (FRA:MFY) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of €16.70 is trading 15% below its estimated GF Value™ of €19.65.

Key valuation signals for FRA:MFY:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €19.65 vs. price of €16.70 (15% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the FRA:MFY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mochida Pharmaceutical Co Business Description

Other Exchanges 4534:Japan
Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
70GF Score

Get the complete analysis for FRA:MFY

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€19.65
GF Value